初始抗菌治疗失败的医院获得性/呼吸机相关性细菌性肺炎患者参加头孢洛扎/他唑巴坦对比美罗培南的3期ASPECT-NP随机对照试验前的结局
ASPECT-NP是一项3期、随机、对照、双盲、多中心、非劣效性试验,比较头孢洛扎/他唑巴坦(3 g[2 g头孢洛扎/1 g他唑巴坦]每8小时一次)与美罗培南(1 g每8小时一次)治疗成人HABP/VABP。本研究为事后分析,纳入研究入组时当前HABP/VABP发作初始抗菌治疗失败的预设亚组(93/726,12.8%)。该亚组中,美罗培南组28天全因死亡率高于头孢洛扎/他唑巴坦组(18/40[45.0%] vs 12/53[22.6%];百分比差异[95% CI]:22.4%[3.1至40.1]),临床治愈率(TOC)分别为37.5% vs 49.1%(百分比差异[95% CI]:11.6%[-8.6至30.2])。多因素回归显示,合并使用血管升压药和美罗培南治疗是与28天全因死亡风险显著相关的因素;调整血管升压药使用后,头孢洛扎/他唑巴坦治疗后的死亡风险约为美罗培南治疗后的四分之一。
要点
- 在初始抗菌治疗失败的HABP/VABP亚组(93/726,12.8%)中,美罗培南组28天全因死亡率高于头孢洛扎/他唑巴坦组(18/40[45.0%] vs 12/53[22.6%];百分比差异[95% CI]:22.4%[3.1至40.1])。
- 该亚组TOC临床治愈率头孢洛扎/他唑巴坦组26/53[49.1%] vs 美罗培南组15/40[37.5%](百分比差异[95% CI]:11.6%[-8.6至30.2]),差异未达统计学显著。
- 多因素回归显示,合并使用血管升压药和美罗培南治疗是与28天全因死亡风险显著相关的因素;调整血管升压药使用后,头孢洛扎/他唑巴坦治疗后的死亡风险约为美罗培南治疗后的四分之一。
- 该分析为事后分析,亚组分析未设计非劣效性检验,结论需谨慎解读。
适用人群与场景
- 成人HABP/VABP患者,需机械通气,且在研究入组时当前HABP/VABP发作初始抗菌治疗失败(预设亚组)。
处置流程与药物剂量
- 头孢洛扎/他唑巴坦:3 g(2 g头孢洛扎/1 g他唑巴坦)每8小时一次,静脉给药(原文未明确疗程)。
- 美罗培南:1 g每8小时一次,静脉给药(原文未明确疗程)。
研究设计与关键结果
- 研究设计:3期、随机、对照、双盲、多中心、非劣效性试验(ASPECT-NP,NCT02070757),比较头孢洛扎/他唑巴坦与美罗培南治疗成人HABP/VABP;主要终点为28天全因死亡率,关键次要终点为TOC临床应答。
- 亚组人群:研究入组时初始抗菌治疗失败者93/726(12.8%),其中头孢洛扎/他唑巴坦组n=53,美罗培南组n=40。
- 28天全因死亡率:美罗培南组18/40(45.0%) vs 头孢洛扎/他唑巴坦组12/53(22.6%);百分比差异(95% CI):22.4%(3.1至40.1)。
- TOC临床应答率:头孢洛扎/他唑巴坦组26/53(49.1%) vs 美罗培南组15/40(37.5%);百分比差异(95% CI):11.6%(-8.6至30.2)。
- 多因素回归:合并使用血管升压药和美罗培南治疗是与28天全因死亡风险显著相关的因素;调整血管升压药使用后,头孢洛扎/他唑巴坦治疗后的死亡风险约为美罗培南治疗后的四分之一。
证据类型、等级与局限
- 证据类型:3期随机对照试验的事后分析。
- 亚组分析未设计非劣效性检验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该事后分析进一步支持先前显示的初始治疗失败的HABP/VABP患者中头孢洛扎/他唑巴坦组28天全因死亡率低于美罗培南组,尽管临床治愈率无显著差异。
指南或共识出处
- ASPECT-NP试验(NCT02070757,2014年2月25日注册)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in adults. Participants in the ASPECT-NP trial received ceftolozane/tazobactam (3 g [2 g ceftolozane/1 g tazobactam] every 8 h) or meropenem (1 g every 8 h). Participants failing prior antibacterial therapy for the current HABP/VABP episode at study entry had lower 28-day all-cause mortality (ACM) rates with ceftolozane/tazobactam versus meropenem treatment. Here, we report a post hoc analysis examining this result.
METHODS: The phase 3, randomized, controlled, double-blind, multicenter, noninferiority trial compared ceftolozane/tazobactam versus meropenem for treatment of adults with ventilated HABP/VABP; eligibility included those failing prior antibacterial therapy for the current HABP/VABP episode at study entry. The primary and key secondary endpoints were 28-day ACM and clinical response at test of cure (TOC), respectively. Participants who were failing prior therapy were a prospectively defined subgroup; however, subgroup analyses were not designed for noninferiority testing. The 95% CIs for treatment differences were calculated as unstratified Newcombe CIs. Post hoc analyses were performed using multivariable logistic regression analysis to determine the impact of baseline characteristics and treatment on clinical outcomes in the subgroup who were failing prior antibacterial therapy.
RESULTS: In the ASPECT-NP trial, 12.8% of participants (93/726; ceftolozane/tazobactam, n = 53; meropenem, n = 40) were failing prior antibacterial therapy at study entry. In this subgroup, 28-day ACM was higher in participants who received meropenem versus ceftolozane/tazobactam (18/40 [45.0%] vs 12/53 [22.6%]; percentage difference [95% CI]: 22.4% [3.1 to 40.1]). Rates of clinical response at TOC were 26/53 [49.1%] for ceftolozane/tazobactam versus 15/40 [37.5%] for meropenem (percentage difference [95% CI]: 11.6% [- 8.6 to 30.2]). Multivariable regression analysis determined concomitant vasopressor use and treatment with meropenem were significant factors associated with risk of 28-day ACM. Adjusting for vasopressor use, the risk of dying after treatment with ceftolozane/tazobactam was approximately one-fourth the risk of dying after treatment with meropenem.
CONCLUSIONS: This post hoc analysis further supports the previously demonstrated lower ACM rate for ceftolozane/tazobactam versus meropenem among participants who were failing prior therapy, despite the lack of significant differences in clinical cure rates.
CLINICALTRIALS: gov registration NCT02070757 . Registered February 25, 2014, clinicaltrials.gov/ct2/show/NCT02070757 .
参考来源
- Kollef MH, Timsit JF, Martin-Loeches I, et al. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem. Crit Care. 2022. PMID: 36457059. doi:10.1186/s13054-022-04192-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。